For the second time this year, the U.S. CDC’s Advisory Committee on Immunization Practices (ACIP) canceled a scheduled meeting due to a federal judge’s stay that keeps the panel from meeting with its current membership. Typically, ACIP meets three times a year – in February, June and October. The 2026 June meeting was slated for June 23-25. Whether the adcom meets in October will be up to the courts and how far Health and Human Services Secretary Robert Kennedy digs in his heels to maintain a hand-picked committee tilted toward his view of vaccines.

With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the latest installment of BioWorld’s series on the BCI field, Rotem Kopel, CEO of Ability Neurotech SA, explains that following in the footsteps of the established players has its advantages. “It's not too bad to be a fast follower to a company like Neuralink.” Ability and its peers are either building more complete systems, or exploring different approaches from electrodes with newer materials to nanoparticles, while addressing technical and clinical challenges identified by earlier entrants and targeting different indications.

When it comes to vaccines and preparedness, platform delivery technologies can be both a boon and a barrier. On the one hand, an existing platform can speed development of a vaccine targeting an unexpected viral scare such as the recent Bundibugyo Ebola and Andes hantavirus outbreaks. On the other hand, the intellectual property (IP) protecting that platform adds to the economic hurdles facing smaller vaccine developers, Douglas Bucklin, a life sciences patent attorney with Volpe Koenig, told BioWorld.

Eli Lilly and Co. posted $19.8 billion in first-quarter 2026 revenue, driven by tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for obesity. The Indianapolis-based drugmaker is channeling cash flow from these blockbuster GLP-1 drugs into an aggressive dealmaking campaign — about $25.1 billion across 10 announced acquisitions so far this year and more than $26 billion in other closed deals.

The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced players, with fully developed BCI systems, the sector is approaching an inflection point as the technology transitions from early feasibility studies into pivotal trials. The focus now for many is on generating the long-term safety, efficacy and real-world usability data needed to support regulatory approval and broader clinical adoption.

The U.S. FDA approved 24 drugs in May 2026, the busiest month of the year so far. Up from April’s 14, it brings the year-to-date total to 84 approvals. Through May, the agency has cleared 20 new molecular entities, a pace that, if sustained, would put 2026 on track to approach or exceed several recent years.

The industry is stepping up its campaign to persuade European governments to increase their drugs budgets, in what is described as a landmark report making the case that spending on patented drugs is not a cost to be contained, but an investment in health and the economy.

Decades of research are helping unravel the “black box” of the brain. The second article in BioWorld’s series on the Brain-Computer Interface (BCI) field looks at how simultaneous breakthroughs in AI technology are pushing the BCI field from a theoretical concept to a potential real-world, clinical option for individuals, particularly in China where the National Medical Products Administration greenlighted the world’s first invasive BCI system – Neuracle Medical Technology Co. Ltd.’s Neural Electronic Opportunity – for clinical use in March 2026.

More and more individuals now have chronically implanted brain-computer interface (BCI) systems in their heads. Devices that can record and stimulate neural signals are increasingly moving from labs to real-world settings to test their potential to treat neurological disorders. At the same time, startups are emerging, investors are pouring money into the space and companies are accelerating their development programs. After decades of clinical research and false starts, are BCI systems finally here?